Related Experiment Video
Updated: Aug 9, 2026
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Development of a live attenuated dengue virus vaccine using reverse genetics
Joseph E Blaney1, Anna P Durbin, Brian R Murphy
1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892-8133, USA. jblaney@niaid.nih.gov
Viral Immunology
|March 24, 2006
Summary
A new tetravalent dengue vaccine candidate was developed using reverse genetics to protect against all four dengue virus serotypes. This live attenuated vaccine shows promise in preventing dengue fever and severe dengue hemorrhagic fever/dengue shock syndrome.
Area of Science:
- Virology
- Vaccinology
- Public Health
Background:
- Dengue virus (DEN1-4) is endemic in tropical regions, transmitted by Aedes aegypti mosquitoes.
- Dengue infection causes asymptomatic illness, dengue fever (DF), or severe dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS).
- A licensed dengue vaccine is currently unavailable, highlighting an urgent need for prevention strategies.
Purpose of the Study:
- To develop a live attenuated, tetravalent dengue vaccine candidate using reverse genetics.
- To achieve attenuation and immunogenicity for all four dengue virus serotypes.
Main Methods:
- Generated recombinant DEN (rDEN) viruses through deletion mutations (Delta30) and antigenic chimerization.
- Modified DEN1 and DEN4 with a 30-nucleotide deletion in the 3' untranslated region.
- Replaced structural proteins of rDEN4Delta30 with those from DEN2 or DEN3 to create chimeric viruses.
Main Results:
- Successfully attenuated four monovalent vaccine candidates (rDEN1, rDEN2, rDEN3, rDEN4) for use in rhesus monkeys or humans.
- Formulated an immunogenic tetravalent vaccine candidate combining the attenuated serotypes.
- Demonstrated that attenuation levels can be enhanced with additional characterized mutations.
Conclusions:
- A live attenuated tetravalent dengue vaccine candidate has been successfully generated.
- The vaccine candidate is capable of providing immunity against all four dengue virus serotypes.
- Further attenuation is possible, offering flexibility for vaccine development.
